BioLight Life Sciences Ltd. (TLV:BOLT)

Market Cap	34.65M +75.0%
Revenue (ttm)	21.00K -91.3%
Net Income	-14.05M
EPS	-2.92
Shares Out	9.05M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,955
Average Volume	11,343
Open	391.10
Previous Close	391.10
Day's Range	377.00 - 383.50
52-Week Range	314.10 - 702.00
Beta	0.03
RSI	55.56
Earnings Date	Mar 23, 2026

About BioLight Life Sciences

BioLight Life Sciences Ltd., an ophthalmic company, engages in the discovery, development, and commercialization of products and product candidates that address ophthalmic conditions. The company’s ophthalmic product offering and pipeline of product candidates include DiagnosTear’s TeaRx technology, a diagnostic platform for diagnosis of disease in the frontal areas of the eye through examination of a number of substances in the composition of teardrops; ViSci, an Eye D technology that treats glaucoma by the insertion of a sub conjunctival impl...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 4
• Stock Exchange: Tel Aviv Stock Exchange
• Ticker Symbol: BOLT

Financial Performance

In 2024, BioLight Life Sciences's revenue was 219,000, an increase of 85.59% compared to the previous year's 118,000. Losses were -7.14 million, -72.55% less than in 2023.